Mark H. Einstein - Concepedia

Concepedia

Author

Mark H. Einstein

Albert Einstein College of Medicine ORCID

Also Known As

Christina Chu, Einstein, Mark, M H Einstein, M. Einstein, M.H. Einstein, MARK H. EINSTEIN, Mark Einstein, Mark H. Einstein

49

Publications

1.6K

Citations

20

H-Index

46

Concepts

All Affiliations

Albert Einstein College of Medicine Montefiore Medical Center Yeshiva University Columbia University Creighton University

MH

About

Mark H. Einstein is an author at Albert Einstein College of Medicine specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	15	879
2	Public Health	4	4	134
3	Health Sciences	1	1	15
4	Nursing	1	1	20
5	Social Sciences	1	1	43

Mark H. Einstein

×

23

Publications

1.6K

Citations

20

H-Index

	Year	Citations
A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer Marc J. Gunter, Donald R. Hoover, Herbert Yu, Cancer Epidemiology Biomarkers & Prevention	2008	261
Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors Gloria S. Huang, Juliana Gebb, Mark H. Einstein, American Journal of Obstetrics and Gynecology Gynecological SurgeryMedical ImagingCancer DetectionGynecologyHigh-grade Endometrial Tumors	2007	146
Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice Dinesh Chandra, Arthee Jahangir, Wilber Quispe‐Tintaya, British Journal of Cancer	2013	140
Metformin use and endometrial cancer survival Nicole Nevadunsky, Anne Van Arsdale, Howard D. Strickler, Gynecologic Oncology MedicineCancer ManagementGynecologyMetformin UseCancer Treatment	2013	131
Obesity and Age at Diagnosis of Endometrial Cancer Nicole Nevadunsky, Anne Van Arsdale, Howard D. Strickler, Obstetrics and Gynecology	2014	109
A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer N. Colombo, Scott McMeekin, Peter E. Schwartz, Journal of Clinical Oncology Advanced Endometrial CancerSingle AgentProgressive Endometrial CancerMedicineCancer Management	2007	100
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Ignace Vergote, Giovanni Scambia, David M. O’Malley, The Lancet Oncology Advanced Ovarian CancerMedicinePharmacologyGynecologyFirst-line Treatment	2019	85
Expression of COX-2, Ki-67, Cyclin D1, and P21 in Endometrial Endometrioid Carcinomas Qianwen Cao, Mark H. Einstein, Patrick Anderson, International Journal of Gynecological Pathology Cox-2 Overexpression ResultsTumoral PathologyCyclin D1MedicineGynecology	2002	76
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper Thomas J. Herzog, Deborah K. Armstrong, Mark F. Brady, Gynecologic Oncology Gynecological SurgeryMedicineCancer ManagementClinical EndpointReproductive Health	2013	69
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma Gloria S. Huang, Lydia G. Chiu, Juliana Gebb, Gynecologic Oncology Tumoral PathologyEndocrine-related CancerMedicinePathologyGynecology	2007	69

Page 1